{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T14:29:05Z","timestamp":1747232945636,"version":"3.40.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.10.018","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T13:54:27Z","timestamp":1544018067000},"page":"220-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Diet-dependent toxicity of ipilimumab in metastatic melanoma"],"prefix":"10.1016","volume":"106","author":[{"given":"P.","family":"Majenka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"R\u00f6tzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-9472","authenticated-orcid":false,"given":"A.","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Koschny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Longerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2018.10.018_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2018.10.018_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.10.018_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2017.06.021","article-title":"Risk of treatment-related mortality in cancer patients treated with ipilimumab: a systematic review and meta-analysis","volume":"83","author":"Zhang","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2018.10.018_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.10.018_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-017-2267-z","article-title":"Immune checkpoint inhibitor colitis: the flip side of the wonder drugs","volume":"472","author":"Assarzadegan","year":"2018","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.ejca.2018.10.018_bib6","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-12-3080","article-title":"Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control","volume":"19","author":"Robert","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2018.10.018_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bjc.2017.274","article-title":"Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers","volume":"117","author":"Hopkins","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.10.018_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-beta 1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2018.10.018_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2018.10.018_bib10","first-page":"5141","article-title":"Effects of an alkaline diet on EGFR-TKI therapy in EGFR mutation-positive NSCLC","volume":"37","author":"Hamaguchi","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2018.10.018_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2018.01.088","article-title":"Dose-dependent toxicity of ipilimumab in metastatic melanoma","volume":"95","author":"Olischewsky","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2018.10.018_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.10.018_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","article-title":"Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases","volume":"99","author":"Williams","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2018.10.018_bib14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.10.018_bib15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/cbr.2010.0865","article-title":"Releasing the brake on the immune system: ipilimumab in melanoma and other tumors","volume":"25","author":"Tarhini","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"10.1016\/j.ejca.2018.10.018_bib16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.gtc.2017.08.012","article-title":"Dietary therapies in pediatric inflammatory bowel disease: an evolving inflammatory bowel disease paradigm","volume":"46","author":"Lane","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.ejca.2018.10.018_bib17","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.ejca.2018.10.018_bib18","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.10.018_bib19","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jand.2015.04.016","article-title":"The specific carbohydrate diet for inflammatory bowel disease: a case series","volume":"115","author":"Kakodkar","year":"2015","journal-title":"J Acad Nutr Diet"},{"issue":"4","key":"10.1016\/j.ejca.2018.10.018_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/2225-4110.139111","article-title":"Dietary agents and phytochemicals in the prevention and treatment of experimental ulcerative colitis","volume":"4","author":"Saxena","year":"2014","journal-title":"J Tradit Complement Med"},{"issue":"6","key":"10.1016\/j.ejca.2018.10.018_bib21","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.10.018_bib22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ni.3754","article-title":"Nutrition, inflammation and cancer","volume":"18","author":"Zitvogel","year":"2017","journal-title":"Nat Immunol"},{"issue":"6371","key":"10.1016\/j.ejca.2018.10.018_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.ejca.2018.10.018_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.ejca.2018.10.018_bib25","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ejca.2018.10.018_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrmicro.2017.44","article-title":"Anticancer effects of the microbiome and its products","volume":"15","author":"Zitvogel","year":"2017","journal-title":"Nat Rev Microbiol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491831459X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491831459X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T14:27:17Z","timestamp":1544797637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491831459X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":26,"alternative-id":["S095980491831459X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.10.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diet-dependent toxicity of ipilimumab in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}